GE HealthCare (GEHC)

Medical imaging + AI diagnostics (GE HealthCare) — imaging hardware + AI-enabled diagnostics

AI exposure 9% — derived from reported segment revenue, not asserted.

Where it sits

Frontier & Emerging Bets → Healthcare AI & Medtech · figures rebased to Q2 2026, reported 2026-07-29

MRI, CT, X-ray, molecular imaging systems (AI-enabled diagnostics) leads 4 businesses in this sub-tier that together are 100% of revenue, so Healthcare AI & Medtech is effectively the whole company rather than one leg of it.

Reported segments

• Advanced Imaging Solutions — 71.2% of revenue
• Pharmaceutical Diagnostics — 15.9% of revenue
• Patient Care Solutions — 12.7% of revenue

GE HealthCare ($5.3B Q2 2026, +5.7% YoY). RESTRUCTURED this quarter: Imaging and Advanced Visualization were merged into a single Advanced Imaging Solutions segment, taking four reportable segments to three. Advanced Imaging Solutions 71.2% ($3,771M, +7.9%) = primary B7 Healthcare AI & Medtech — MRI, CT, X-ray, molecular imaging and ultrasound with AI-assisted reconstruction and workflow; Pharmaceutical Diagnostics 15.9% ($843M, +15.6% — the fastest leg); Patient Care Solutions 12.7% ($675M, -13.3%).

How the 9% is built

• Advanced Imaging Solutions — 71.2% of revenue × 12% AI-driven (disclosed). AI-assisted reconstruction and workflow are embedded in the scanners, but the revenue is imaging hardware and service
• Pharmaceutical Diagnostics — 15.9% of revenue × 0% AI-driven (disclosed). Contrast agents and radiopharmaceuticals — consumables with no AI content
• Patient Care Solutions — 12.7% of revenue × 5% AI-driven (disclosed). Monitoring and diagnostic cardiology with some algorithmic analysis

Investment read

Moat. Top-three imaging franchise alongside Siemens Healthineers and Philips — installed base, service annuity and clinical-validation barriers — now converting a nine-product launch cycle, including Photonova Spectra photon-counting CT (FDA-cleared March 2026), into orders: record organic orders +11.1%, book-to-bill 1.15x, and an all-time-high $23.9B backlog.

Bottleneck / pricing power. Moderate, and currently compressing rather than expanding: adjusted EBIT margin 14.2% in Q2 2026, down ~40bps YoY, against a reaffirmed 15.4-15.7% full-year guide that requires a steep H2 ramp. China (~10% of revenue) is still declining under VBP, and Amneal's generic iohexol pressures Omnipaque. Pharmaceutical Diagnostics (+15.6% to $843M, led by Flyrcado) is the one line with genuine pricing.

Role in the AI stack. The medical-imaging + AI-diagnostics layer.

Connected companies

• Siemens (SIEGY) — GEHC competes with: medical imaging + diagnostics — Siemens Healthineers vs GE HealthCare (the two field leaders)
• NVIDIA (NVDA) — GEHC is supplied by: GPUs/AI compute for GE HealthCare imaging AI (NVIDIA partnership)

Others in Healthcare AI & Medtech

• Intuitive Surgical (ISRG)

All 174 companies · What moved this quarter · How the map is built